Evidence map›Paper›PMID 26806585›Full record

ArticleBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2016

Proceedings from the Second Haploidentical Stem Cell Transplantation Symposium-Haplo2014, San Francisco, California, December 4, 2014.

Monzr M Al Malki, Mary Horowitz, Rupert Handgretinger, Wing Leung, Denis-Claude Roy, Xiao-Jun Huang, Ephraim Fuchs, Franco Locatelli, Didier Blaise, Shin Mineishi and 10 more

Open access · greenAbstract readConference Proceedings
In one paragraph

Article in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Haploidentical Related Donor Hematopoietic Stem Cell Transplantation for Dedicator-of-Cytokinesis 8 Deficiency Using Post-Transplantation Cyclophosphamide.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2017
    Article
  5. Review
  6. First Successful Haploidentical Stem Cell Transplantation in Romania.Romanian journal of internal medicine = Revue roumaine de medecine interne · 2016
    Article
  7. Immunity to Infections after Haploidentical Hematopoietic Stem Cell Transplantation.Mediterranean journal of hematology and infectious diseases · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors at 17 institutions in 6 countries.

Monzr M Al MalkiCity of Hope National Medical Center, Duarte, California.
Mary HorowitzCenter for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, Wisconsin.
Rupert HandgretingerChildrens University Hospital, Tuebingen, Germany.
Wing LeungSt. Jude Children's Research Hospital, Memphis, Tennessee.
Denis-Claude RoyUniversity of Montreal, Montreal, Canada.
Xiao-Jun HuangPeking University Institute of Hematology, Beijing, China.
Ephraim FuchsJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Franco LocatelliBambino Gesu Children's Hospital, Rome, Italy.
Didier BlaiseInstitute Paoli Calmettes, Marseille, France.
Shin MineishiUniversity of Alabama at Birmingham, Birmingham, Alabama.
Massimo MartelliPerugia University, Perugia, Italy.
Jeffrey MillerUniversity of Minnesota, Minneapolis, Minnesota.
Carl JuneUniversity of Pennsylvania, Philadelphia, Pennsylvania.
Hui-Sheng AiAffiliated Hospital of the Academy of Military Medical Sciences, Beijing, China.
Leo LuznikJohns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland.
Domenico MavilioHumanitas Clinical and Research Center, Milan, Italy.
Enrico LugliHumanitas Clinical and Research Center, Milan, Italy.
Marcel R M van den BrinkMemorial Sloan Kettering Cancer Center, New York, New York.
Richard E ChamplinUniversity of Texas MD Anderson Cancer Center, Houston, Texas.
Stefan O CiureaUniversity of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: sciurea@mdanderson.org.
Humanitas University · ITSidney Kimmel Comprehensive Cancer Center · USThe University of Texas MD Anderson Cancer Center · USAcademy of Military Medical Sciences · CNBambino Gesù Children's Hospital · ITCity Of Hope National Medical Center · USInstitut Paoli-Calmettes · FRMedical College of Wisconsin · USMemorial Sloan Kettering Cancer Center · USPeking University · CNSt. Jude Children's Research Hospital · USUniversité de Montréal · CAUniversity Children's Hospital Tübingen · DEUniversity of Alabama at Birmingham · USUniversity of Minnesota System · USUniversity of Pennsylvania · USUniversity of Perugia · IT

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

Significant progress has been made over the past decade in haploidentical transplantation, with the development of novel methods to control intense alloreactive reactions generated in the major HLA-mismatched setting. Application of post-transplantation cyclophosphamide has gained worldwide acceptance as an effective and low-cost way to perform this type of transplantation, with outcomes now similar to those from HLA-matched unrelated donors. These advances have resulted in improved treatment-related mortality, whereas disease relapse has emerged as the most common cause of treatment failure. In addition, improvements in immunologic reconstitution after transplantation are much needed, not only in haploidentical transplantation but in all forms of stem cell transplantation. This symposium has focused on some of the most promising methods to control alloreactivity in this form of transplantation and application of cellular therapy to prevent disease relapse after transplantation, as well as understanding immunologic reconstitution and foreseeable approaches to improve immune recovery after transplantation.

Indexed as

Stem Cell TransplantationAnimalsAntineoplastic Agents, AlkylatingClinical Trials as TopicCyclophosphamideDisease Models, AnimalGraft vs Host DiseaseHematologic NeoplasmsHistocompatibility TestingHLA AntigensHumansMiceRecurrenceSan FranciscoSecondary PreventionSurvival AnalysisAntineoplastic Agents, AlkylatingCyclophosphamideHLA AntigensCellular therapyHaploidentical transplantationImmunologic reconstitution after transplantationPost-transplantation cyclophosphamideT cell depleted

Identifiers

PMID26806585
PMCPMC7104805
OpenAlexW2258948347

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.